Abstract
Balanol, a fungal metabolite, is a potent ATP-competitive inhibitor of Protein Kinase C (PKC) and Protein Kinase A (PKA), important targets in oncology. Since its discovery in 1993, a number of studies have been performed in order to design selective and bioavailable balanol analogs. Several crystal structures of PKA in complex with balanol and a few analogs bound within the catalytic site have also been solved providing insight about the key interactions for binding. The PKA-balanol complex has also served as an interesting model system for structurebased ligand design and validation of a number of computational methodologies aimed at both understanding the physical basis for molecular recognition and addressing the important issue of protein flexibility in ligand binding. We provide an overview of the structure-activity relationships of balanol analogs and summarize the progress made in structural and computational studies involving balanol.
Keywords: Balanol, structure activity relationships, kinases, computational chemistry, x-ray crystal structure, protein flexibility, adenosine triphosphate
Anti-Cancer Agents in Medicinal Chemistry
Title: The Protein Kinase Inhibitor Balanol: Structure – Activity Relationships and Structure-Based Computational Studies
Volume: 8 Issue: 6
Author(s): Vineet Pande, Maria J. Ramos and Federico Gago
Affiliation:
Keywords: Balanol, structure activity relationships, kinases, computational chemistry, x-ray crystal structure, protein flexibility, adenosine triphosphate
Abstract: Balanol, a fungal metabolite, is a potent ATP-competitive inhibitor of Protein Kinase C (PKC) and Protein Kinase A (PKA), important targets in oncology. Since its discovery in 1993, a number of studies have been performed in order to design selective and bioavailable balanol analogs. Several crystal structures of PKA in complex with balanol and a few analogs bound within the catalytic site have also been solved providing insight about the key interactions for binding. The PKA-balanol complex has also served as an interesting model system for structurebased ligand design and validation of a number of computational methodologies aimed at both understanding the physical basis for molecular recognition and addressing the important issue of protein flexibility in ligand binding. We provide an overview of the structure-activity relationships of balanol analogs and summarize the progress made in structural and computational studies involving balanol.
Export Options
About this article
Cite this article as:
Pande Vineet, Ramos J. Maria and Gago Federico, The Protein Kinase Inhibitor Balanol: Structure – Activity Relationships and Structure-Based Computational Studies, Anti-Cancer Agents in Medicinal Chemistry 2008; 8 (6) . https://dx.doi.org/10.2174/187152008785133056
DOI https://dx.doi.org/10.2174/187152008785133056 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Variability in Reward Responsivity and Obesity: Evidence from Brain Imaging Studies
Current Drug Abuse Reviews Research Toward Potassium Channels on Tumor Progression
Current Topics in Medicinal Chemistry Protective Effect of NSAIDs on Cancer and Influence of COX-2 C G Genotype
Current Cancer Drug Targets Paraneoplastic Pemphigus: Autoimmune-Cancer Nexus in the Skin
Anti-Cancer Agents in Medicinal Chemistry The Effects of Nanoencapsulated Curcumin-Fe3O4 on Proliferation and hTERT Gene Expression in Lung Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Cetuximab Inhibits Gastric Cancer Growth in vivo, Independent of KRAS Status
Current Cancer Drug Targets Magnetic Nanoparticles for Cancer Therapy
Current Nanoscience New Insight Into A1 Adenosine Receptors in Diabetes Treatment
Current Pharmaceutical Design Toll-Like Receptors in Alzheimer's Disease: A Therapeutic Perspective
CNS & Neurological Disorders - Drug Targets Pluronic-Based Core/Shell Nanoparticles for Drug Delivery and Diagnosis
Current Medicinal Chemistry Biology of PPARγ in Cancer: A Critical Review on Existing Lacunae
Current Molecular Medicine Cancer Immunotherapy: An Effective Tool in Cancer Control and Treatment
Current Cancer Therapy Reviews Cellular Interactions of Virion Infectivity Factor (Vif) as Potential Therapeutic Targets: APOBEC3G and More?
Current Drug Targets Protein Interaction Networks in Metallo Proteins and Docking Approaches of Metallic Compounds with TIMP and MMP in Control of MAPK Pathway
Letters in Drug Design & Discovery Anaplastic Lymphoma Kinase Inhibitors in Non-Small Cell Lung Cancer
Current Drug Targets Adding to the Mix: Fibroblast Growth Factor and Platelet-Derived Growth Factor Receptor Pathways as Targets in Non – small Cell Lung Cancer
Current Cancer Drug Targets Structural Comparison of the Interaction of Tubulin with Various Ligands Affecting Microtubule Dynamics
Current Cancer Drug Targets TRAIL: A Potential Agent for Cancer Therapy
Current Molecular Medicine Toxins Targeting Voltage-Activated Ca<sup>2+</sup> Channels and their Potential Biomedical Applications
Current Topics in Medicinal Chemistry Isoindole Derivatives: Propitious Anticancer Structural Motifs
Current Topics in Medicinal Chemistry